FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Baxter Recalls Life2000 Ventilators

FDA says Baxter is recalling its Life2000 ventilators that were distributed in the U.S. between 8/2023 and 4/2024 due to potential battery charger don...

latest-news-card-1
Federal Register

Notice of Eylea Biosimilar Patent Infringement Suit

Federal Register notice: FDA provides notice that a patent infringement lawsuit has been filed against Amgen over its BLA submission for a biosimilar ...

latest-news-card-1
Federal Register

Guide on Opioid Use Disorder Devices

Federal Register notice: FDA makes available final guidance entitled Clinical Considerations for Studies of Devices Intended To Treat Opioid Use Disor...

latest-news-card-1
Human Drugs

3 Observations on Hikma FDA-483

FDA releases the form FDA-483 with three observations issued following an inspection at the Hikma outsourcing facility in Cherry Hill, NJ.

Human Drugs

5 Themes in Innovative Trial Approach Meeting

The Duke-Margolis Institute for Health Policy issues a summary with five broad themes from a meeting co-sponsored with FDA on increasing clinical tria...

latest-news-card-1
Human Drugs

Pfizer Taps Oral Danuglipron Formulation for Obesity

Pfizer selects its preferred once-daily modified-release formulation for danuglipron, an oral glucagon-like peptide-1 receptor agonist it is developin...

latest-news-card-1
Biologics

Complete Response on Novo Nordisk Insulin Icodec

FDA issues Novo Nordisk a complete response letter on its BLA for once-weekly basal insulin icodec, indicated for treating diabetes mellitus.

latest-news-card-1
FDA General

Senate Gives FDA $170 Million Boost for FY 2025

The Senate Appropriations Committee marks up and approves FDAs fiscal year (FY) 2025 budget, providing a $170 million (2.5%) boost over the FY 2024 sp...

latest-news-card-1
Human Drugs

Payers Should Help in Evidence Generation: Report

FDA researchers stress the need for more payer involvement in evidence generation to support clinical practice following drug approvals.

latest-news-card-1
Human Drugs

Arcutis Biotherapeutics Zoryve OKd for Atopic Dermatitis

FDA approves an Arcutis Biotherapeutics supplemental NDA for Zoryve (roflumilast) cream, 0.15%, for treating mild to moderate atopic dermatitis.